“…In the last four years, several systematic reviews and meta-analyses were published [ 15 , 16 , 17 , 25 , 27 , 29 , 31 , 32 , 41 ], most of them with the aim to define the disease burden of RSV in older adults and some of them with the active participation of pharma companies involved in RSV vaccine and drug development. Several clinical studies have been published over the years worldwide [ 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 ]. In Europe, what emerged together with the findings of few multicenter clinical studies [ 21 , 59 , 60 , 61 , 62 , 63 , 64 , 65 ] was the need to harmonize and collaborate between the various laboratories in order to obtain shared diagnostic protocols with which to compare data...…”